


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313 on January 23, 2006.

SUBMISSION OF SEQUENCE LISTING
UNDER 37 CFR §§1.821-1.825
Patent Application
Docket No. ARS-106
Serial No. 10/517,726


Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Amanda Proudfoot, Marie Kosco-Vilbois
Serial No. : 10/517,726
Filed : December 10, 2004
Conf. No. : 6045
For : Novel Antagonists of CXCR3-Binding CXC Chemokines

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

SUBMISSION OF SEQUENCE LISTING UNDER 37 CFR §§1.821-1.825


Sir:

Transmitted herewith is a replacement Sequence Listing Under 37 CFR §§1.821 through 1.825 for the above-identified patent application. A Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) was received from the Patent and Trademark Office which indicated that the subject application does not comply with the sequence requirements of 37 CFR §§1.821-1.825. A copy of the Notification is enclosed herewith. Also enclosed is an Amendment Under 37 CFR §1.825(a) through (c).

The Sequence Listing is submitted in computer readable format and on paper. I hereby certify that the paper and computer readable copies contain the same information and that no new material is added by this submission.

The Commissioner is hereby authorized to charge any fees under 37 CFR 1.16 or 1.17 as required by this paper to Deposit Account No. 19-0065.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950
Gainesville, FL 32614-2950

FCE/sl

Enclosures: Sequence listing in computer readable format and on paper; Copy of Notification of Missing Requirements